http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013150330-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B1-041 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B1-00 |
| filingDate | 2012-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013150330-A |
| titleOfInvention | SULPHATE SALTS AS ACCELERATORS OF ACCESS TIME |
| abstract | 1. A method of studying the interior of the patient’s gastrointestinal tract using capsule endoscopy, comprising: administering to the patient a sulfate solution for oral administration in an amount effective to cleanse the patient’s gastrointestinal tract from its contents and free the gastrointestinal tract, the sulfate solution for oral use, it is an accelerator of passage and contains from about 0.0096 g / ml to about 0.50 g / ml of sulfate in the form of an inorganic sulfate salt and not with holding phosphate salt; orally administering to the patient activated capsule endoscope, the reception device for the placement of recording data transmitted activated capsular endoscope as it passes through the interior of the patient's gastrointestinal tract; and analysis of the data recorded by the receiver before and / or after the inserted capsule endoscope is removed from the patient’s colon. 2. The method according to claim 1, where the sulfate salt in the composition of the sulfate solution for oral administration contains magnesium sulfate, sodium sulfate and / or potassium sulfate. The method according to claim 2, wherein the solution contains sodium sulfate, potassium sulfate and magnesium sulfate. The method according to claim 3, where the sulfate solution for oral administration contains from about 0.0095 g / ml to about 0.038 g / ml sodium, from about 0.002 g / ml to about 0.009 g / ml potassium, from about 0.0005 g / ml to about 0.05 g / ml magnesium and from about 0.02 g / ml to about 0.1 g / ml sulfate. 5. The method according to claim 4, wherein from about 15 ml to about 1000 ml of sulfate solution is administered |
| priorityDate | 2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.